Free Trial

STERIS (STE) Competitors

STERIS logo
$207.49 +3.15 (+1.54%)
(As of 12/20/2024 05:16 PM ET)

STE vs. BDX, EW, IDXX, RMD, DXCM, PODD, HOLX, BAX, GMED, and MASI

Should you be buying STERIS stock or one of its competitors? The main competitors of STERIS include Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), IDEXX Laboratories (IDXX), ResMed (RMD), DexCom (DXCM), Insulet (PODD), Hologic (HOLX), Baxter International (BAX), Globus Medical (GMED), and Masimo (MASI). These companies are all part of the "health care equipment" industry.

STERIS vs.

STERIS (NYSE:STE) and Becton, Dickinson and Company (NYSE:BDX) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, community ranking, risk and dividends.

STERIS pays an annual dividend of $2.28 per share and has a dividend yield of 1.1%. Becton, Dickinson and Company pays an annual dividend of $4.16 per share and has a dividend yield of 1.8%. STERIS pays out 52.1% of its earnings in the form of a dividend. Becton, Dickinson and Company pays out 70.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. STERIS has raised its dividend for 20 consecutive years and Becton, Dickinson and Company has raised its dividend for 53 consecutive years. Becton, Dickinson and Company is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Becton, Dickinson and Company has higher revenue and earnings than STERIS. Becton, Dickinson and Company is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
STERIS$5.33B3.85$378.24M$4.3847.37
Becton, Dickinson and Company$20.18B3.26$1.71B$5.9438.33

94.7% of STERIS shares are owned by institutional investors. Comparatively, 87.0% of Becton, Dickinson and Company shares are owned by institutional investors. 1.1% of STERIS shares are owned by company insiders. Comparatively, 0.3% of Becton, Dickinson and Company shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

STERIS currently has a consensus target price of $262.50, suggesting a potential upside of 26.51%. Becton, Dickinson and Company has a consensus target price of $283.50, suggesting a potential upside of 24.52%. Given STERIS's higher possible upside, equities analysts plainly believe STERIS is more favorable than Becton, Dickinson and Company.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
STERIS
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80
Becton, Dickinson and Company
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00

STERIS has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Comparatively, Becton, Dickinson and Company has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500.

In the previous week, Becton, Dickinson and Company had 23 more articles in the media than STERIS. MarketBeat recorded 26 mentions for Becton, Dickinson and Company and 3 mentions for STERIS. STERIS's average media sentiment score of 1.63 beat Becton, Dickinson and Company's score of 0.26 indicating that STERIS is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
STERIS
3 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Becton, Dickinson and Company
5 Very Positive mention(s)
5 Positive mention(s)
5 Neutral mention(s)
3 Negative mention(s)
1 Very Negative mention(s)
Neutral

Becton, Dickinson and Company received 262 more outperform votes than STERIS when rated by MarketBeat users. Likewise, 62.32% of users gave Becton, Dickinson and Company an outperform vote while only 58.98% of users gave STERIS an outperform vote.

CompanyUnderperformOutperform
STERISOutperform Votes
335
58.98%
Underperform Votes
233
41.02%
Becton, Dickinson and CompanyOutperform Votes
597
62.32%
Underperform Votes
361
37.68%

Becton, Dickinson and Company has a net margin of 8.55% compared to STERIS's net margin of 8.02%. Becton, Dickinson and Company's return on equity of 14.89% beat STERIS's return on equity.

Company Net Margins Return on Equity Return on Assets
STERIS8.02% 13.78% 8.28%
Becton, Dickinson and Company 8.55%14.89%6.98%

Summary

Becton, Dickinson and Company beats STERIS on 12 of the 21 factors compared between the two stocks.

Get STERIS News Delivered to You Automatically

Sign up to receive the latest news and ratings for STE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

STE vs. The Competition

MetricSTERISSurgical appliances & supplies IndustryMedical SectorNYSE Exchange
Market Cap$20.48B$9.53B$5.12B$19.18B
Dividend Yield1.08%1.37%4.91%3.59%
P/E Ratio47.3719.5691.3441.28
Price / Sales3.8532.801,116.6317.59
Price / Cash15.2622.3742.5821.28
Price / Book3.255.494.795.32
Net Income$378.24M$182.72M$120.07M$989.88M
7 Day Performance-3.14%-4.48%-1.90%-3.56%
1 Month Performance-3.84%-4.23%11.43%-3.70%
1 Year Performance-5.01%-12.17%30.59%12.12%

STERIS Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
STE
STERIS
4.9352 of 5 stars
$207.49
+1.5%
$262.50
+26.5%
-3.5%$20.48B$5.33B47.3718,179Positive News
High Trading Volume
BDX
Becton, Dickinson and Company
4.8867 of 5 stars
$230.94
+2.4%
$283.50
+22.8%
-5.1%$66.77B$20.18B37.9774,000Analyst Downgrade
Insider Trade
Analyst Revision
EW
Edwards Lifesciences
3.9397 of 5 stars
$73.50
+0.2%
$79.40
+8.0%
+0.9%$43.35B$6.00B10.7419,800
IDXX
IDEXX Laboratories
4.9794 of 5 stars
$433.51
+0.3%
$539.63
+24.5%
-23.6%$35.50B$3.84B41.6711,000
RMD
ResMed
4.5281 of 5 stars
$241.25
+1.1%
$227.91
-5.5%
+36.4%$35.41B$4.81B31.599,980Positive News
DXCM
DexCom
4.9146 of 5 stars
$76.53
-0.9%
$98.00
+28.1%
-31.4%$29.89B$3.95B46.229,600
PODD
Insulet
4.2483 of 5 stars
$265.85
-1.3%
$267.44
+0.6%
+28.2%$18.65B$1.70B46.123,000Positive News
HOLX
Hologic
4.7212 of 5 stars
$72.94
-1.0%
$89.50
+22.7%
+1.9%$16.55B$4.03B22.147,063Analyst Forecast
BAX
Baxter International
4.5944 of 5 stars
$29.56
-2.5%
$40.45
+36.9%
-23.6%$15.09B$15.06B149.2060,000Options Volume
GMED
Globus Medical
4.8787 of 5 stars
$82.25
-0.2%
$92.18
+12.1%
+59.4%$11.20B$2.48B122.675,000Analyst Forecast
Analyst Revision
MASI
Masimo
3.5617 of 5 stars
$176.83
+0.4%
$170.67
-3.5%
+49.0%$9.47B$2.04B121.485,200Analyst Forecast

Related Companies and Tools


This page (NYSE:STE) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners